var data={"title":"Naloxone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Naloxone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6623?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=naloxone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Naloxone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Naloxone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50353046\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Narcan Interim Order to Expire</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada is advising health care providers that the Canadian authorized version of Narcan will transition onto the market by July 5, 2017. In July 2016, an Interim Order was issued that permitted the importation, sale, and distribution of Narcan approved in the United States for 1 year. On July 5, 2017, the Interim Order will expire. Product obtained under the Interim Order can continue to be used, but new orders will be for the Canadian-authorized Narcan product. There will be a period of time in which both products will be available.</p>\n        <p style=\"text-indent:0em;\">For further information, visit http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63784a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25063978\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Evzio;</li>\n      <li>Narcan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2980444\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Naloxone Hydrochloride Injection;</li>\n      <li>Naloxone Hydrochloride Injection USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199499\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Opioid Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199464\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Available routes of administration include IV (preferred), IM, SubQ, and intranasal; other available routes (off-label) include inhalation via nebulization (adults only), and intraosseous (IO). Endotracheal administration is the least desirable and is supported by only anecdotal evidence (case report) (AHA [Neumar 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Opioid overdose:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> For the initial treatment of an opioid-associated life-threatening emergency, the American Heart Association recommends, after initiation of CPR, the use of intranasal or IM naloxone with a repeat dose as needed. If there is an initial patient response (ie, purposeful movement, regular breathing, moan or other response) but the patient then stops responding, begin CPR and repeat naloxone dose. If no initial response, continue CPR and use AED as appropriate (AHA [Lavonas 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, IM, SubQ: Initial: 0.4 to 2 mg; may need to repeat doses every 2 to 3 minutes. A lower initial dose (0.1 to 0.2 mg) should be considered for patients with opioid dependence to avoid acute withdrawal or if there are concerns regarding concurrent stimulant overdose (Mokhlesi 2003). After reversal, may need to readminister dose(s) at a later interval (ie, 20 to 60 minutes) depending on type/duration of opioid. If no response is observed after 10 mg total, consider other causes of respiratory depression. <b>Note:</b> May be given endotracheally (off-label route) as 2 to 2.5 times the initial IV dose (ie, 0.8 to 5 mg) (AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, SubQ: Evzio: 0.4 mg or 2 mg (contents of 1 auto-injector) as a single dose; may repeat every 2 to 3 minutes until emergency medical assistance becomes available.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous infusion (off-label dosing):</i> IV: <b>Note:</b> For use with exposures to long-acting opioids (eg, methadone), sustained release product, and symptomatic body packers after initial naloxone response. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein 1984) <b>or</b> use two-thirds (<sup>2</sup>/<sub>3</sub>) of the initial effective naloxone bolus on an hourly basis (typically 0.25 to 6.25 mg/hour); one-half (<sup>1</sup>/<sub>2</sub>) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank 1986).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation via nebulization (off-label route): 2 mg; may repeat. Switch to IV or IM administration when possible (Weber 2012).<b> Note: </b>This administration method is not included in the AHA recommendations for initial management of opioid-associated life-threatening emergency (AHA [Lavonas 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: <b>Note:</b> Onset of action is slightly delayed compared to IM or IV routes (Kelly 2005; Robertson 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 mg (contents of 1 nasal spray) as a single dose in one nostril; may repeat every 2 to 3 minutes in alternating nostrils until medical assistance becomes available.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Off label dosing: 2 mg (1 mg per nostril) using generic injectable solution (with a mucosal atomization device); may repeat in 3 to 5 minutes if respiratory depression persists (AHA [Lavonas 2015]; AHA [Vanden Hoek 2010]; Kelly 2005; Robertson 2009; Walley 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of respiratory depression with therapeutic opioid doses:</b> IV: Initial: 0.02 to 0.2 mg; titrate to avoid profound withdrawal, seizures, arrhythmias, or severe pain (APS 2008; Doyon 2010; AHA [Lavonas 2015]). <b>Note:</b> May be given endotracheally (off-label route) as 2 to 2.5 times the initial recommended IV dose (ie, 0.04 to 0.5 mg) (AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous infusion (off-label dosing):</i> IV: <b>Note:</b> For use with exposures to long-acting opioids (eg, methadone) or sustained release products. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein 1984) <b>or</b> use two-thirds (<sup>2</sup>/<sub>3</sub>) of the initial effective naloxone bolus on an hourly basis (typically 0.2 to 0.6 mg/hour); one-half (<sup>1</sup>/<sub>2</sub>) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank 1986).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Opioid-dependent patients being treated for cancer pain (off-label dosing):</i> IV: <b>Note:</b> May dilute 0.4 mg/mL (1 mL) ampule into 9 mL of normal saline for a total volume of 10 mL to achieve a 0.04 mg/mL (40 <b>mcg</b>/mL) concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.02 mg (20 <b>mcg</b>) IV push; administer every 2 minutes until improvement in symptoms (APS guidelines, v.6.2008) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.04 to 0.08 mg (40 to 80 <b>mcg</b>) slow IV push; administer every 30 to 60 seconds until improvement in symptoms; if no response is observed after total naloxone dose 1 mg, consider other causes of respiratory depression. If respiratory depression is due to long-acting opioids, may consider administering naloxone as a continuous infusion starting at 66% of the total bolus dose (or 0.2 mg per hour) to reverse the opioid toxicity (Howlett 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Postoperative reversal:</i> IV: 0.1 to 0.2 mg every 2 to 3 minutes until desired response (adequate ventilation and alertness without significant pain). <b>Note:</b> Repeat doses may be needed within 1 to 2 hour intervals depending on type, dose, and timing of the last dose of opioid administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid-induced pruritus (off-label use):</b> IV infusion: 0.25 <b>mcg/kg/hour</b> (Gan 1997). Doses up to ~3 <b>mcg/kg/hour</b> have been employed (Kendrick 1996). However, doses &gt;2 <b>mcg/kg/hour</b> are more likely to lead to reversal of analgesia and are not recommended (Kjellberg 2001; Miller 2011). <b>Note:</b> Monitor pain control; verify that the naloxone is not reversing analgesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199481\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Naloxone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid overdose:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PALS Guidelines <i>(off-label dosing)</i> (AHA [Kleinman 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (preferred), intraosseous (off-label route): <b>Note:</b> May be administered IM, SubQ, or endotracheal (off-label route), but onset of action may be delayed, especially if patient has poor perfusion; endotracheal preferred if IV/intraosseous route not available; doses may need to be repeated. <b>Note:</b> The use of naloxone is not recommended as part of initial resuscitative efforts in the delivery room for neonates with respiratory depression; support ventilation to improve oxygenation and heart rate (AHA [Kattwinkel 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children &lt;5 years or &le;20 kg (off-label dose): 0.1 mg/kg/dose (maximum dose: 2 mg); repeat every 2 to 3 minutes if needed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;5 years or &gt;20 kg and Adolescents: 2 mg; if no response, repeat every 2 to 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endotracheal (off-label route): Infants, Children, and Adolescents: Optimal endotracheal dose unknown; current expert recommendations are 2 to 3 times the IV dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children and Adolescents: Initial: 0.01 mg/kg/dose; if no response, a subsequent dose of 0.1 mg/kg may be given</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Continuous IV infusion (off-label dosing):</i> Infants, Children and Adolescents: 24 to 40 mcg/kg/hour has been reported (Gourlay 1983; Lewis 1984; Tenenbein 1984). Doses as low as 2.5 mcg/kg/hour have been reported in adults and a dose of 160 mcg/kg/hour was reported in one neonate (Tenenbein 1984). If continuous infusion is required, calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein 1984) or use two-thirds of the initial effective naloxone bolus on an hourly basis; titrate dose. <b>Note: </b>The infusion should be discontinued by reducing the infusion in decrements of 25%; closely monitor the patient (eg, pulse oximetry and respiratory rate) after each adjustment and after discontinuation of the infusion for recurrence of opioid-induced respiratory depression (Perry 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, SubQ: Infants, Children and Adolescents: Initial: 0.01 mg/kg/dose; if no response, a subsequent dose of 0.1 mg/kg may be given; <b>Note:</b> If using IM or SubQ route, dose should be given in divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Auto-injector: Evzio: Neonates, Infants, Children and Adolescents: 0.4 mg or 2 mg (contents of 1 auto-injector) as a single dose; may repeat every 2 to 3 minutes until emergency medical assistance becomes available.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: Neonates, Infants, Children and Adolescents: 4 mg (contents of 1 nasal spray) as a single dose in one nostril; may repeat every 2 to 3 minutes in alternating nostrils until medical assistance becomes available. <b>Note:</b> Onset of action is slightly delayed compared to IM or IV routes (Kelly 2005; Robertson 2009). In neonates with known or suspected exposure to maternal opioid use, consider using another form of naloxone to allow dosing according to weight and titration to effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of respiratory depression with therapeutic opioid dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PALS guidelines <i>(off-label dosing)</i> (AHA [Kleinman 2010]): Infants, Children, and Adolescents: IV: 0.001 to 0.005 mg/kg/dose; titrate to effect. <b>Note:</b> AAP recommends a wider dosage range of 0.001 to 0.015 mg/kg/dose (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling: Infants, Children, and Adolescents: IV: Initial: 0.005 to 0.01 mg; repeat every 2 to 3 minutes as needed based on response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199465\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210045\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210046\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199436\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Narcan: 4 mg/0.1 mL (1 ea) [contains benzalkonium chloride, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/mL (1 mL); 4 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evzio: 0.4 mg/0.4 mL (0.4 mL); 2 mg/0.4 mL (0.4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Cartridge, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199421\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199440\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV push: Administer over 30 seconds as undiluted preparation <b>or </b>administer as diluted preparation slow IV push by diluting 0.4 mg (1 mL) ampul with 9 mL of normal saline for a total volume of 10 mL to achieve a concentration of 0.04 mg/mL (APS 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV continuous infusion: Dilute to 4 <b>mcg</b>/mL in D<sub>5</sub>W or normal saline</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, SubQ: May administer IM or SubQ if unable to obtain IV access</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Auto-injector: For IM or SubQ use only. Intended for buddy administration; the person administering the medication should follow the printed instructions on the device or the electronic voice instructions coming from the speaker on the device. If the voice instruction system does not operate properly, the device will still deliver the intended dose of naloxone when properly administered. Administer IM or SubQ into the anterolateral aspect of the thigh; may be injected through clothing. When being administered to infants &lt;1 year of age, the thigh muscle should be pinched during administration. Following proper administration, a red indicator appears in the viewing window; the needle is not visible before, during, or after the injection. Patients who received naloxone in the out-of-hospital setting should seek immediate emergency medical assistance after the first dose due to the likelihood that respiratory and/or central nervous system depression will return. Repeat doses may be required until emergency medical assistance becomes available; a new device must be used as each device contains a single dose of naloxone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endotracheal (off-label route): There is only anecdotal support for this route of administration. May require a slightly higher dose than used in other routes. Dilute to 1 to 2 mL with normal saline; flush with 5 mL of saline and then administer 5 ventilations (AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation via nebulization (off-label route): Dilute 2 mg of naloxone with 3 mL of normal saline and administer via nebulizer face mask (Mycyk 2003; Weber 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administer initial dose as soon as possible. Do not prime or test the device prior to administration. Administer in alternating nostrils with each dose. Place the patient in the supine position and provide support to the back of the neck to allow the head to tilt back. Following administration, turn the patient on their side. Each container contains a single intranasal spray, do not reuse; if repeat administration is necessary a new container must be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate intranasal administration instructions using generic injectable solution:</i> Administer total dose equally divided into each nostril using a mucosal atomization device (MAD) (AHA [Vanden Hoek 2010]; Kelly 2005; Robertson 2009). If a MAD is not available, the solution may be sprayed into the nares without a MAD; however, a significant amount of drug may be lost likely due to swallowing and subsequent first-pass metabolism (Dowling 2008; Robinson 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199439\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid overdose:</b> For the complete or partial reversal of opioid depression (including respiratory depression) induced by natural and synthetic opioids (eg, propoxyphene, methadone, nalbuphine, butorphanol, pentazocine). Naloxone is also indicated for the diagnosis of suspected or known acute opioid overdosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Evzio (IM, SubQ) intranasal:</i> For the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or CNS depression. Intended for immediate administration as emergency therapy in settings where opioids may be present. Not a substitute for emergency medical care.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25732507\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Opioid-induced pruritus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199507\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naloxone may be confused with Lanoxin, nalbuphine, naltrexone </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Narcan may be confused with Marcaine, Norcuron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Narcan [multiple international markets] may be confused with Marcen brand name for ketazolam [Spain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199428\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing (parenteral), hypertension, hypotension, tachycardia, ventricular fibrillation, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, body pain, brain disease, coma, confusion (parenteral), disorientation (parenteral), dizziness (parenteral), excessive crying (neonates), hallucination (parenteral), headache (nasal), hyperreflexia (neonates), irritability, nervousness, outbursts of anger (parenteral), paresthesia (parenteral), restlessness, seizure (neonates), shivering, tonic-clonic seizures (parenteral), withdrawal syndrome, yawning</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, piloerection, xeroderma (nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash (parenteral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, constipation (nasal), diarrhea, nausea, toothache (nasal), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site (parenteral), injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle spasm (nasal), musculoskeletal pain (nasal), tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dry nose (nasal), dyspnea, hypoxia (parenteral), nasal congestion (nasal), nasal discomfort (pain; nasal), nasal mucosa swelling (nasal), pulmonary edema, respiratory depression (parenteral), rhinitis (nasal), rhinorrhea, sneezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199443\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to naloxone or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199425\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute opioid withdrawal: Administration of naloxone causes the release of catecholamines, which may precipitate acute withdrawal or unmask pain in those who regularly take opioids. Symptoms of acute withdrawal in opioid-dependent patients may include pain, tachycardia, hypertension, fever, sweating, abdominal cramps, diarrhea, nausea, vomiting, agitation, and irritability. In neonates born to mothers with opioid dependence, opioid withdrawal may be life-threatening and symptoms may include excessive crying, shrill cry, failure to feed, seizures, and hyperactive reflexes. In settings other than acute opioid overdose (eg, postoperative patients), carefully titrate the dose to reverse hypoventilation; do not fully awaken patient or reverse analgesic effect. The 2 mg nasal dose (off-label) is less likely to precipitate severe opioid withdrawal compared to the 4 mg dose; however, the 2 mg dose may not provide an adequate and timely reversal in patients who have been exposed to an overdose of a potent or very high dose of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or in patients receiving medications with potential adverse cardiovascular effects (eg, hypotension, pulmonary edema or arrhythmias); pulmonary edema and cardiovascular instability, including ventricular fibrillation, have been reported in association with abrupt reversal when using opioid antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use caution in patients with history of seizures; avoid use in the treatment of meperidine-induced seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Auto-injector: When administered to infants &lt;1 year of age, monitor the injection site for residual needle parts and signs of infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Addiction involving opioid use: To prevent overdose deaths, there are initiatives to dispense naloxone for self- or buddy-administration to patients at risk of opioid overdose (eg, recipients of high-dose opioids, suspected or confirmed history of illicit opioid use) and individuals likely to be present in an overdose situation (eg, family members of illicit drug users) (Albert 2011; Bennett 2011). Clinical practice guidelines recommend patients being treated for opioid use disorder should be given prescriptions for naloxone. Patients and family members/significant others should be trained in the use of naloxone in overdose (Kampman [ASAM 2015]). Evzio is indicated for emergency treatment. Needleless administration via nebulization and the intranasal route using the injectable solution (with a mucosal atomization device) by first responders and bystanders has also been described (Doe-Simkins 2009; Weber 2012). Needleless administration provides an alternative route of administration in patients with venous scarring due to illicit drug use (eg, heroin). There is a low incidence of death following naloxone reversal of opioid toxicity in patients who refuse transport to a healthcare facility (Wampler 2011). Nevertheless, patients who received naloxone in the out-of-hospital setting should seek immediate emergency medical assistance after the first dose due to the likelihood that respiratory and/or central nervous system depression will return.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Opioid overdose: Recurrence of respiratory and/or CNS depression is possible if the opioid involved is long-acting; continuously observe patients until there is no further risk of recurrent respiratory or CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Partial opioid agonist and mixed opioid agonist/antagonist overdose: Reversal of partial opioid agonists or mixed opioid agonist/antagonists (eg, buprenorphine, pentazocine) may be incomplete and larger or repeat doses of naloxone may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postoperative reversal: Appropriate use: Excessive dosages should be avoided after use of opioids in surgery. Abrupt postoperative reversal may result in nausea, vomiting, sweating, tachycardia, hypertension, seizures, and other cardiovascular events (including pulmonary edema and arrhythmias).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299739\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199430\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9678&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Methylnaltrexone: May enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: Opioid Antagonists may enhance the adverse/toxic effect of Naldemedine. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: Opioid Antagonists may enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199432\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (product-specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199446\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Naloxone crosses the placenta and may precipitate opioid withdrawal in the fetus.  Naloxone is not recommended for use in pregnant women with opioid use disorder except in situations of life threatening overdose (Kampman [ASAM 2015]). Use to diagnose opioid dependence during pregnancy is contraindicated (ACOG 2012). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Use caution in pregnant women with mild-to-moderate hypertension during labor; severe hypertension may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199447\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if naloxone is present in breast milk, however, systemic absorption following oral administration is low (Smith 2012) and any exposure of naloxone to a breastfeeding infant would therefore be limited. Since naloxone is used for opioid reversal, the opioid concentrations in the milk of a breastfeeding mother and potential transfer of the opioid to the infant should be considered. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199434\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory rate, heart rate, blood pressure, temperature, level of consciousness, ABGs or pulse oximetry</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199424\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pure opioid antagonist that competes and displaces opioids at opioid receptor sites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199442\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Endotracheal, IM, SubQ: 2 to 5 minutes; Inhalation via nebulization: ~5 minutes (Mycyk 2003); Intranasal: ~8 to 13 minutes (Kelly 2005; Robertson 2009); IV: ~2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: ~30 to 120 minutes depending on route of administration; IV has a shorter duration of action than IM administration; since naloxone's action is shorter than that of most opioids, repeated doses are usually needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Intranasal, IM, SubQ: Pediatric patients: May be erratic or delayed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Relatively weak (to albumin [major] and other plasma constituents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic via glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 43% to 54% (nasal compared to 0.4 mg IM dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM, SubQ: 15 minutes; Intranasal: 19.8 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Neonates: Mean 3.1 &plusmn; 0.5 hours; Adults: IM, IV, or SubQ: 0.5 to 1.5 hours; Intranasal: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323451\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Narcan Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4MG/0.1ML (1): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Naloxone HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/mL (1 mL): $18.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/10 mL (10 mL): $141.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Evzio Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/0.4 mL (0.4 mL): $2,250.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/0.4 mL (0.4 mL): $2,460.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (Naloxone HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/mL (1 mL): $18.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Naloxone HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/2 mL (2 mL): $39.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F199448\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Feng Du (CN);</li>\n      <li>Intrenon (CZ);</li>\n      <li>Jin Er Lun (CN);</li>\n      <li>Mapin (HK, MY);</li>\n      <li>Min-I-Jet Naloxone (GB);</li>\n      <li>N-Xone (LK);</li>\n      <li>Nalone (FR);</li>\n      <li>Naloxon (BG, CH, DE, IS);</li>\n      <li>Naloxone Hydrochlorid (GB);</li>\n      <li>Naloxonum Hydrochloricum (PL);</li>\n      <li>Naloxonum Prolongatum (PL);</li>\n      <li>Narcan (AE, AU, BE, BF, BH, BJ, BR, CI, CY, EG, ET, FR, GB, GH, GM, GN, GR, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PK, PL, QA, SA, SC, SD, SG, SL, SN, SY, TN, TW, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Narcanti (AT, DK, HN, HU, MX, NO, PL, UY);</li>\n      <li>Narcotan (IN);</li>\n      <li>Narlox (PH);</li>\n      <li>Narxona (AR);</li>\n      <li>Naxone (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nex (LK);</li>\n      <li>Nexodal (FI, IE, LT, NL, PT, SE, SI);</li>\n      <li>Opaxon (BD);</li>\n      <li>Oxogina (VE);</li>\n      <li>Prenoxad (GB);</li>\n      <li>Zynox (ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Health Care for Underserved Women and American Society of Addiction Medicine. ACOG Committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy. <i>Obstet Gynecol</i>. 2012;119(5):1070-1076.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/22525931/pubmed\" target=\"_blank\" id=\"22525931\">22525931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albert S, Brason FW, Sanford CK, et al, &quot;Project Lazarus: Community-Based Overdose Prevention in Rural North Carolina,&quot; <i>Pain Med</i>, 2011, 12(Suppl 2):77-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/21668761/pubmed\" target=\"_blank\" id=\"21668761\">21668761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society. <i>Principles of Amalgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 6th ed. Glenview, IL: American Pain Society; 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bennett AS, Bell A, Tomedi EG, et al, &quot;Characteristics of an Overdose Prevention, Response, and Naloxone Distribution Program in Pittsburgh and Allegheny County, Pennsylvania,&quot; <i>J Urban Health</i>, 2011, 88(6):1020-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/21773877/pubmed\" target=\"_blank\" id=\"21773877\">21773877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergasa NY, Alling DW, Talbot TL, et al, &ldquo;Effects of Naloxone Infusions in Patients With the Pruritus of Cholestasis. A Double-Blind, Randomized, Controlled Trial,&rdquo; <i>Ann Intern Med</i>, 1995, 123(3):161-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7598296/pubmed\" target=\"_blank\" id=\"7598296\">7598296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boeuf B, Gauvin F, Guerguerian AM, et al, &ldquo;Therapy of Shock With Naloxone: A Meta-Analysis,&rdquo; <i>Crit Care Med</i>, 1998, 26(11):1910-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/9824088/pubmed\" target=\"_blank\" id=\"9824088\">9824088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW, &ldquo;Management of Opioid Analgesic Overdose,&rdquo; <i>N Engl J Med</i>, 2012, 367(2):146-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/22784117/pubmed\" target=\"_blank\" id=\"22784117\">22784117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chamberlain JM and Klein BL, &ldquo;A Comprehensive Review of Naloxone for the Emergency Physician,&rdquo; <i>Am J Emerg Med</i>, 1994, 12(6):650-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7945608/pubmed\" target=\"_blank\" id=\"7945608\">7945608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doe-Simkins M, Walley AY, Epstein A, et al, &ldquo;Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose,&rdquo; <i>Am J Public Health</i>, 2009, 99(5):788-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/19363214/pubmed\" target=\"_blank\" id=\"19363214\">19363214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. <i>Ther Drug Monit</i>. 2008;30(4):490-496.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/18641540/pubmed\" target=\"_blank\" id=\"18641540\">18641540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doyon S. Chapter 180. Opioids. In: Tintinalli J, Stapczynski JS, Ma OJ, et al. <i>Tintinalli's Emergency Medicine</i>. 7th ed. New York, NY: McGraw-Hill; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Pediatric Emergencies,&rdquo; <i>Pediatrics</i>, 1998, 101(1):E13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/9734990/pubmed\" target=\"_blank\" id=\"9734990\">9734990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evzio 0.4 mg per 0.4 mL (naloxone hydrochloride) [prescribing information]. Richmond, VA: Kaleo; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evzio 2 mg per 0.4 mL (naloxone hydrochloride) [prescribing information]. Richmond, VA: Kaleo; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer CG and Cook DR, &ldquo;The Respiratory and Narcotic Antagonistic Effects of Naloxone in Infants,&rdquo; <i>Anesth Anal</i>, 1974, 53(6):849-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/4473926/pubmed\" target=\"_blank\" id=\"4473926\">4473926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9366459\"></a>Gan TJ, Ginsberg B, Glass PS, et al, &ldquo;Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate,&rdquo; <i>Anesthesiology</i>, 1997, 87(5):1075-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/9366459/pubmed\" target=\"_blank\" id=\"9366459\">9366459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3963538\"></a>Goldfrank L, Weisman RS, Errick JK, et al, &ldquo;A Dosing Nomogram for Continuous Infusion Intravenous Naloxone,&rdquo; <i>Ann Emerg Med</i>, 1986, 15(5):566-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/3963538/pubmed\" target=\"_blank\" id=\"3963538\">3963538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gourlay GK, Coulthard K. The role of naloxone infusions in the treatment of overdoses of long half-life narcotic agonists: application to nor-methadone. <i>Br J Clin Pharmacol</i>. 1983;15(2):269-271.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/6849762/pubmed\" target=\"_blank\" id=\"6849762\">6849762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hantson P, Evenepoel E, Ziade D, et al, &ldquo;Adverse Cardiac Manifestations Following Dextropropoxyphene Overdose: Can Naloxone Be Helpful?&rdquo; <i>Ann Emerg Med</i>, 1995, 25(2):263-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7832361/pubmed\" target=\"_blank\" id=\"7832361\">7832361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoffman RS and Goldfrank LR, &ldquo;The Poisoned Patient With Altered Consciousness. Controversies in the Use of a 'Coma Cocktail',&rdquo; <i>JAMA</i>, 1995, 274(7):562-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7629986/pubmed\" target=\"_blank\" id=\"7629986\">7629986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howlett C, Gonzalez R, Yerram P, Faley B. Use of naloxone for reversal of life-threatening opioid toxicity in cancer-related pain. <i>J Oncol Pharm Pract.</i> 2016;22(1):114-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/25227231/pubmed\" target=\"_blank\" id=\"25227231\">25227231</a>]</span><span class=\"doi\">10.1177/1078155214551589</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson C, Mayer P, and Grosz D, &ldquo;Pulmonary Edema Following Naloxone Administration in a Healthy Orthopedic Patient,&rdquo; <i>J Clin Anesth</i>, 1995, 7(4):356-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7546765/pubmed\" target=\"_blank\" id=\"7546765\">7546765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan JL, Marx JA, Calabro JJ, et al, &ldquo;Double-Blind, Randomized Study of Nalmefene and Naloxone in Emergency Department Patients With Suspected Narcotic Overdose,&rdquo; <i>Ann Emerg Med</i>, 1999, 34(1):42-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/10381993/pubmed\" target=\"_blank\" id=\"10381993\">10381993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-367. doi:10.1097/ADM.0000000000000166. http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf?sfvrsn=1826406300</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kattwinkel J, Perlman JM, Aziz K, et al. Part 15: neonatal resuscitation: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):909-919.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/20956231/pubmed\" target=\"_blank\" id=\"20956231\">20956231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15651944\"></a>Kelly A, Kerr D, Dietze P, et al, &ldquo;Randomised Trial of Intranasal Versus Intramuscular Naloxone in Prehospital Treatment for Suspected Opioid Overdose,&rdquo; <i>Med J Aust</i>, 2005, 182(1):24-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/15651944/pubmed\" target=\"_blank\" id=\"15651944\">15651944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kendrick WD, Woods AM, Daly MY, et al, &ldquo;Naloxone Versus Nalbuphine Infusion for Prophylaxis of Epidural Morphine-Induced Pruritus,&rdquo; <i>Anesth Analg</i>, 1996, 82(3):641-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/8623975/pubmed\" target=\"_blank\" id=\"8623975\">8623975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kjellberg F and Tramer MR, &ldquo;Pharmacological Control of Opioid-Induced Pruritus: A Quantitative Systematic Review of Randomized Trials,&rdquo; <i>Eur J Anaesthesiol</i>, 2001, 18(6):346-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/11412287/pubmed\" target=\"_blank\" id=\"11412287\">11412287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: special circumstances of resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18)(suppl 2):S501-S518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/26472998/pubmed\" target=\"_blank\" id=\"26472998\">26472998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis JM, Klein-Schwartz W, Benson BE, et al. Continuous naloxone infusion in pediatric narcotic overdose. <i>Am J Dis Child</i>. 1984;138(10):944-946.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/6475855/pubmed\" target=\"_blank\" id=\"6475855\">6475855</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merigian KS, &ldquo;Cocaine-Induced Ventricular Arrhythmias and Rapid Atrial Fibrillation Temporally Related to Naloxone Administration,&rdquo; <i>Am J Emerg Med</i>, 1993, 11(1):96-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/8447884/pubmed\" target=\"_blank\" id=\"8447884\">8447884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller JL, Hagemann TM. Use of pure opioid antagonists for management of opioid-induced pruritus. <i>Am J Health Syst Pharm</i>. 2011;68(15):1419-1425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/21785031/pubmed\" target=\"_blank\" id=\"21785031\">21785031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mycyk MB, Szyszko AL, and Aks SE, &ldquo;Nebulized Naloxone Gently and Effectively Reverses Methadone Intoxication,&rdquo; <i>J Emerg Med</i>, 2003, 24(2):185-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/12609650/pubmed\" target=\"_blank\" id=\"12609650\">12609650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naloxone Hydrochloride Injection [prescribing information]. Rockford, IL; Mylan; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Narcan (naloxone hydrochloride) intranasal [prescribing information]. Radnor, PA: Adapt Pharma; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20956256\"></a>Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/20956256/pubmed\" target=\"_blank\" id=\"20956256\">20956256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor PG and Kosten TR, &ldquo;Rapid and Ultrarapid Opioid Detoxification Techniques,&rdquo; <i>JAMA</i>, 1998, 279(3):229-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/9438745/pubmed\" target=\"_blank\" id=\"9438745\">9438745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olsen KS, &ldquo;Naloxone Administration and Laryngospasm Followed by Pulmonary Edema,&rdquo; <i>Intensive Care Med</i>, 1990, 16(5):340-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/2212264/pubmed\" target=\"_blank\" id=\"2212264\">2212264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Malley-Dafner L, Davies P, &ldquo;Naloxone-Induced Pulmonary Edema,&rdquo; <i>Am J Nurs</i>, 2000, 100(11):24AA-JJ.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasero C and McCaffery M, &ldquo;Reversing Respiratory Depression With Naloxone,&rdquo; <i>Am J Nurs</i>, 2000, 100(2):26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/10683639/pubmed\" target=\"_blank\" id=\"10683639\">10683639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry HE and Shannon MW, &ldquo;Diagnosis and Management of Opioid- and Benzodiazepine-Induced Comatose Overdose in Children,&rdquo; <i>Curr Opin Pediatr</i>, 1996, 8(3):243-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/8814402/pubmed\" target=\"_blank\" id=\"8814402\">8814402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20462660\"></a>Phan NQ, Bernhard JD, Luger TA, St&auml;nder S. Antipruritic treatment with systemic &mu;-opioid receptor antagonists: a review. <i>J Am Acad Derm</i>. 2010;63(4):680-688.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/20462660/pubmed\" target=\"_blank\" id=\"20462660\">20462660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society (APS), 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19731165\"></a>Robertson TM, Hendey GW, Stroh G, et al, &ldquo;Intranasal Naloxone is a Viable Alternative to Intravenous Naloxone for Prehospital Narcotic Overdose,&rdquo; <i>Prehosp Emerg Care</i>, 2009, 13(4):512-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/19731165/pubmed\" target=\"_blank\" id=\"19731165\">19731165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. <i>Am J Health Syst Pharm</i>. 2014;71(24):2129-2135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/25465584/pubmed\" target=\"_blank\" id=\"25465584\">25465584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salvucci AA Jr, Eckstein M, and Iscovich AL, &ldquo;Submental Injection of Naloxone,&rdquo; <i>Ann Emerg Med</i>, 1995, 25(5):719-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7741359/pubmed\" target=\"_blank\" id=\"7741359\">7741359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith K, Hopp M, Mundin G, et al, &quot;Low Absolute Bioavailability of Oral Naloxone in Healthy Subjects,&quot; <i>Int J Clin Pharmacol Ther</i>, 2012, 50(5):360-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/22541841/pubmed\" target=\"_blank\" id=\"22541841\">22541841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Storrow AB, Wians FH Jr, Mikkelsen SL, et al, &ldquo;Does Naloxone Cause a Positive Urine Opiate Screen?&rdquo; <i>Ann Emerg Med</i>, 1994, 24(6):1151-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7978599/pubmed\" target=\"_blank\" id=\"7978599\">7978599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tandberg D and Abercrombie D, &ldquo;Treatment of Heroin Overdose With Endotracheal Naloxone,&rdquo; <i>Ann Emerg Med</i>, 1982, 11(8):443-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/7103164/pubmed\" target=\"_blank\" id=\"7103164\">7103164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6481543\"></a>Tenenbein M, &ldquo;Continuous Naloxone Infusion for Opiate Poisoning in Infancy,&rdquo; <i>J Pediatr</i>, 1984, 105(4):645-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/6481543/pubmed\" target=\"_blank\" id=\"6481543\">6481543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trujillo MH, Guerrero J, Fragachan C, et al, &ldquo;Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration,&rdquo; <i>Crit Care Med</i>, 1998, 26(2):377-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/9468179/pubmed\" target=\"_blank\" id=\"9468179\">9468179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Vonderen JJ, Siew ML, Hooper SB, et al, &quot;Effects of Naloxone on the Breathing Pattern of a Newborn Exposed to Maternal Opiates,&quot; <i>Acta Pediatr</i>, 2012, 101(7):e309-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/22372574/pubmed\" target=\"_blank\" id=\"22372574\">22372574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. <i>J Subst Abuse Treat</i>. 2013;44(2):241-247.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/22980450/pubmed\" target=\"_blank\" id=\"22980450\">22980450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wampler DA, Molina DK, McManus J, et al, &quot;No Deaths Associated With Patient Refusal of Transport After Naloxone-Reversed Opioid Overdose,&quot; <i>Prehosp Emerg Care</i>, 2011, 15(3):320-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/21612385/pubmed\" target=\"_blank\" id=\"21612385\">21612385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22191727\"></a>Weber JM, Tataris KL, Hoffman JD, et al, &quot;Can Nebulized Naloxone Be Used Safely and Effectively by Emergency Medical Services for Suspected Opioid Overdose?&quot; <i>Prehosp Emerg Care</i>, 2012, 16(2):289-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/22191727/pubmed\" target=\"_blank\" id=\"22191727\">22191727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weikert LF, Bernard GR. Pharmacotherapy of sepsis. <i>Clin Chest Med</i>. 1996;17(2):289-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/naloxone-drug-information/abstract-text/8792067/pubmed\" target=\"_blank\" id=\"8792067\">8792067</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9678 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50353046\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F25063978\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2980444\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F199499\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F199464\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F199481\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F199465\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20210045\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210046\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F199436\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F199421\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F199440\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F199439\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25732507\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F199507\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F199428\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F199443\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F199425\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299739\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F199430\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F199432\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F199446\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F199447\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F199434\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F199424\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F199442\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323451\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F199448\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9678|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=naloxone-patient-drug-information\" class=\"drug drug_patient\">Naloxone: Patient drug information</a></li><li><a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">Naloxone: Pediatric drug information</a></li></ul></div></div>","javascript":null}